Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bladder Cancer, General Internal Medicine, Kidney Cancer, Prostate Cancer, Testicular Cancer
Education and Experience
Training
- Dekanat der Medizinischen Fakultat (Venusberg )/ (1999)
Residencies
- Johns Hopkins Bayview Medical Center (Baltimore MD)/ Medicine (2002)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology (2009)
Certifications
- Medical Oncology, American Board of Internal Medicine (2011)
- Internal Medicine, American Board of Internal Medicine (2007)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Appointment Phone: 410-955-8964
Location Map
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Expertise
- Bladder Cancer
- General Internal Medicine
- Kidney Cancer
- Prostate Cancer
- Testicular Cancer
Research
Research and Publications
Stebbing, J.; Wood, C.; Atkins, M.; Bukowski, R.; Litwin, S.; Bower, M.; Parsa, A.; Levitsky, H. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer. 2008 Mar 1;112(5):955-961.
Verheul, H.M.; Salumbides, B.; Van Erp, K.; Hammers, H.; Qian, D.Z.; Sanni, T.; Atadja, P.; Pili, R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008 Jun 1;14(11):3589-3597.
Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-19586.
Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009 Aug 8;280(2):145-153.
Georgiades, C.S.; Rodriguez, R.; Littrup, P.J.; Frangakis, C.E.; Leveille, R.; Ahrar, K.; Atwell, T.D.; Cadeddu, J.; Trimmer, C.; Durack, J.C.; Hammers, H.J.; Meng, M.V.; Raman, S.; Solomon, S.B.; Zagoria, R.J.; McLennan, G.; Laberge, J.M.; Gervais, D.A.; Kee, S.T. Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2010 Dec;21(12):1807-1816.
Hammers, H.J.; Verheul, H.M.; Salumbides, B.; Sharma, R.; Rudek, M.; Jaspers, J.; Shah, P.; Ellis, L.; Shen, L.; Paesante, S.; Dykema, K.; Furge, K.; Teh, B.T.; Netto, G.; Pili, R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010 Jun;9(6):1525-1535.
Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.
Koskimaki, J.E.; Karagiannis, E.D.; Tang, B.C.; Hammers, H.; Watkins, D.N.; Pili, R.; Popel, A.S. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer. 2010;10:29.
Verheul, H.M.; Salumbides, B.; Van Erp, K.; Hammers, H.; Qian, D.Z.; Sanni, T.; Atadja, P.; Pili, R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008 Jun 1;14(11):3589-3597.
Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-19586.
Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009 Aug 8;280(2):145-153.
Georgiades, C.S.; Rodriguez, R.; Littrup, P.J.; Frangakis, C.E.; Leveille, R.; Ahrar, K.; Atwell, T.D.; Cadeddu, J.; Trimmer, C.; Durack, J.C.; Hammers, H.J.; Meng, M.V.; Raman, S.; Solomon, S.B.; Zagoria, R.J.; McLennan, G.; Laberge, J.M.; Gervais, D.A.; Kee, S.T. Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2010 Dec;21(12):1807-1816.
Hammers, H.J.; Verheul, H.M.; Salumbides, B.; Sharma, R.; Rudek, M.; Jaspers, J.; Shah, P.; Ellis, L.; Shen, L.; Paesante, S.; Dykema, K.; Furge, K.; Teh, B.T.; Netto, G.; Pili, R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010 Jun;9(6):1525-1535.
Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.
Koskimaki, J.E.; Karagiannis, E.D.; Tang, B.C.; Hammers, H.; Watkins, D.N.; Pili, R.; Popel, A.S. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer. 2010;10:29.
Research Interests
- Prostate cancer
More Info
Languages
- English
- German
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts